Sarah Gordon-Wild

Hy. The private company is based in Dorchester, UK, and their fine art salerooms are centrally located in the county town, close to the main Dorchester South railway station. Duke & Son Ltd. is a British company that deals with militaria and sporting goods, as well as silver and objects of vertu. The company also provides valuations for inheritance tax assessment. The company was founded in 1999, and Lee Young has been the CEO of the company since 2017.

Hy. The private company is based in Dorchester, UK, and their fine art salerooms are centrally located in the county town, close to the main Dorchester South railway station. Duke & Son Ltd. is a British company that deals with militaria and sporting goods, as well as silver and objects of vertu. The company also provides valuations for inheritance tax assessment. The company was founded in 1999, and Lee Young has been the CEO of the company since 2017.

Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom.

Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom.

Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom.

Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom.

Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom.